[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524412":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":47,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Canadian Medical and Surgical Knowledge Translation Research Group","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Type 2 Diabetes",null,"Participants living with type 2 diabetes for less than 10 years will be recruited.",{"label":13,"type":10,"description":14,"interventionNames":10},"No Diabetes","Participants not living with diabetes will be recruited.",[16,20],{"name":17,"affiliation":18,"role":19},"Subodh Verma, MD, PhD","Unity Health Toronto","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":22,"role":19},"David A Hess, PhD","Robarts Research Institute, London, Ontario",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Fallon Dennis, BMSc","CONTACT","7057720021","fallon.dennis@mail.utoronto.ca",[30],{"facility":31,"status":10,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Diagnostic Assessment Centre","Scarborough Village","Ontario","M1S4N6","Canada","CA",{"type":38,"coordinates":39},"Point",[40,41],-79.22124,43.73899,{"lat":41,"lon":40},[44],{"name":17,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[48,49],{"name":18,"class":6},{"name":50,"class":6},"University of Western Ontario, Canada","100524412","functional-investigation-of-endothelial-function-and-regenerative-cell-exhaustion-100524412",false,"NCT06108388","Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion","Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion in Type 2 Diabetes","FIERCE","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Willing to provide written informed consent.\n* Documented history of T2D\n* No documented history of diabetes\n\nExclusion Criteria:\n\n* Unable or unwilling to provide written informed consent or provide a peripheral blood sample.\n* Any life-threatening disease expected to result in death within two years of consent.\n* Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening.\n* Known severe liver disease.\n* White blood cell count ≥15 x 10\\^9\u002FL.\n* Active infectious disease requiring systemic antibiotic or anti-viral agents.\n* Known acquired immunodeficiency syndrome such as HIV.\n* Treated autoimmune disorders (e.g. T1D and LADA).\n* On oral steroid therapy (e.g. prednisone or other corticosteroids) or other immunosuppressive agents (e.g. methotrexate).",true,"ALL","18 Years",{"count":63,"type":64},90,"ESTIMATED","OBSERVATIONAL","FIERCE is an observational cross-sectional study. Approximately 90 individuals living with type 2 diabetes (T2D) and\u002For individuals living without diabetes will be randomized (2:1).\n\nThe primary objective of this trial is to determine if there are differences in the content and function of circulating vascular regenerative (VR) progenitor cell subsets isolated from individuals living with T2D versus individuals not living with T2D. The main question this study aims to answer is: Does T2D compromise or enhance VR cell functionality?\n\nEach participant will be asked to provide a single blood sample. Blood samples will be processed to enumerate the number of vessel-repairing cells and determine the functionality of the different subtypes of vessel-repairing cells.",[68],"Diabetes Mellitus, Type 2",[9,70,71,72,73,74,75,76,77],"Vascular regeneration","Hematopoietic progenitor cells","Functionality","EndoPAT","Endothelial dysfunction","scRNA-seq","Colony formation assay","Secretome analyses","NOT_YET_RECRUITING","2023-11-09",{"date":81,"type":82},"2023-11-13","ACTUAL",{"date":84,"type":64},"2023-11",{"date":86,"type":64},"2026-06",{"name":5,"class":6},1]